Validation of simplified scoring systems for assessing cutaneous disease activity in dermatomyositis

dc.contributor.authorPongtarakulpanit N.
dc.contributor.authorBishnoi A.
dc.contributor.authorChandra T.
dc.contributor.authorDzanko S.
dc.contributor.authorGkiaouraki E.
dc.contributor.authorKeret S.
dc.contributor.authorLomanto Silva R.
dc.contributor.authorSriram S.
dc.contributor.authorSaygin D.
dc.contributor.authorLiarski V.M.
dc.contributor.authorAscherman D.P.
dc.contributor.authorMoghadam-Kia S.
dc.contributor.authorOddis C.V.
dc.contributor.authorAggarwal R.
dc.contributor.correspondencePongtarakulpanit N.
dc.contributor.otherMahidol University
dc.date.accessioned2026-03-05T18:20:18Z
dc.date.available2026-03-05T18:20:18Z
dc.date.issued2026-02-01
dc.description.abstractOBJECTIVES: The Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) is a standard clinician-scored outcome measure for dermatomyositis (DM), but requires expertise and training. We aimed to validate simplified versions of the CDASI activity score. METHODS: Adult DM patients were prospectively enrolled with two clinic visits ≥2 months apart. Two rheumatologists independently assessed patients using the CDASI activity score (range 0-100) and the cutaneous visual analogue scale of the Myositis Disease Activity Assessment Tool (MDAAT cutaneous VAS). Additionally, patients completed the Skindex questionnaire. Four simplifications (sCDASI) were derived: (1) sCDASI-1 (range 0-66), simplified erythema to absent/present (0-1); (2) sCDASI-2 (range 0-36), simplified erythema and exclusion of scale scoring; (3) sCDASI-3 (range 0-20), simplified erythema, exclusion of scale and ulcer scoring; (4) sCDASI-4, (range 0-50), simplification of all parameters to absent/present. RESULTS: Twenty-seven DM patients (81.5% female, 96.3% White, median age 50.0) were included. Median CDASI activity was 4.5 (IQR 1.0-12.0). All sCDASI scores correlated strongly with the full CDASI (Spearman ρ=0.97-0.98), MDAAT cutaneous VAS (Spearman ρ=0.94), and Skindex (Spearman ρ=0.82-0.83), indicating good convergent validity. Inter-rater reliability for all simplifications was high, as indicated by strong correlations between assessors. The changes from baseline in simplified CDASI scores correlated strongly with the changes in full CDASI scores and MDAAT cutaneous VAS, demonstrating good responsiveness. CONCLUSIONS: Simplified CDASI scorings demonstrated preliminary evidence of favourable validity, reliability, and responsiveness in the longitudinal evaluation of rashes in DM patients.
dc.identifier.citationClinical and Experimental Rheumatology Vol.44 No.2 (2026) , 330-338
dc.identifier.doi10.55563/clinexprheumatol/8lq4aq
dc.identifier.issn0392856X
dc.identifier.pmid41678167
dc.identifier.scopus2-s2.0-105031238233
dc.identifier.urihttps://repository.li.mahidol.ac.th/handle/123456789/115554
dc.rights.holderSCOPUS
dc.subjectMedicine
dc.subjectImmunology and Microbiology
dc.titleValidation of simplified scoring systems for assessing cutaneous disease activity in dermatomyositis
dc.typeArticle
mu.datasource.scopushttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=105031238233&origin=inward
oaire.citation.endPage338
oaire.citation.issue2
oaire.citation.startPage330
oaire.citation.titleClinical and Experimental Rheumatology
oaire.citation.volume44
oairecerif.author.affiliationMassachusetts General Hospital
oairecerif.author.affiliationUniversity of Pittsburgh School of Medicine
oairecerif.author.affiliationTechnion - Israel Institute of Technology
oairecerif.author.affiliationUniversity of Pittsburgh Medical Center
oairecerif.author.affiliationRush University Medical Center

Files

Collections